Connecting clinical care, data and research
PartnershipsContact
← Back to publications

RESEARCH PUBLICATION / 2026

Original Article

Incident psoriatic arthritis with SGLT2 versus GLP-1 therapies in patients with type 2 diabetes

Comparative Risk of Psoriatic Arthritis in Type 2 Diabetes: An Emulated Target Trial of SGLT2 Inhibitors vs. GLP-1 Receptor Agonists

Drug Design, Development and Therapy

Citation & Authors

Drug Des Devel Ther. 2026;20:614222.

Fu-Shun Yen; Shiow-Ing Wang; Chii-Min Hwu; Kai-Yang Chen; Chih-Cheng Hsu; James Cheng-Chung Wei

ABSTRACT · CHINESE TRANSLATION

Translated abstract

Translated from the licensed abstract via the Chinese version. This is not an official journal translation.

background

Patients with psoriatic arthritis (PsA) have higher prevalences of type 2 diabetes and cardiovascular events, greater work absenteeism, and lower productivity, potentially affecting life expectancy and quality of life.

purpose

A target trial emulation compared incident PsA risk between SGLT2 inhibitor and GLP-1 receptor agonist users with type 2 diabetes.

method

The TriNetX network identified 188,378 SGLT2 inhibitor users and 213,218 GLP-1 receptor agonist users between January 1, 2016, and December 31, 2024. Propensity score matching yielded 146,810 pairs. The primary causal estimand was the intention-to-treat (ITT) effect of each treatment strategy. Kaplan–Meier analyses estimated outcome probabilities; HRs and confidence intervals were calculated, and the proportional hazards assumption was tested.

result

SGLT2 inhibitor users had a significantly lower risk of incident PsA, with an HR of 0.793 (95% CI 0.667–0.944) over 5 years. Testing supported the proportional hazards assumption (p>0.05), and Kaplan–Meier curves showed a significantly lower cumulative incidence (log-rank p=0.008). The association was consistent after adjustment for multiple covariates and was supported by an intention-to-treat sensitivity analysis.

Conclusion

This multicenter target trial emulation found that SGLT2 inhibitors were associated with a lower risk of incident PsA than GLP-1 receptor agonists. However, this was an observational study, and residual confounding may persist despite extensive adjustment. The findings should be interpreted cautiously and confirmed in prospective and randomized studies.

Original work: Author of the above paper. Source:Public Summary ↗. This translation is based on the Chinese rendering of the original English abstract.

Original work license:CC BY-NC ↗;Translations are subject to the same licensing conditions.

Key findings

Propensity score matching yielded 146,810 pairs. Over 5 years, SGLT2 inhibitor use was associated with a lower risk of incident psoriatic arthritis than GLP-1 receptor agonist use (HR 0.793; 95% CI 0.667–0.944).

This target trial emulation used observational data, and residual confounding may remain. The findings show associations rather than established causality and require validation in prospective and randomized studies.